MOH | Drug Subsidies & Schemes

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Abacavir & Lamivudine	Tablet	Abacavir 600 mg + Lamivudine 300 mg	SDL
Abacavir, Dolutegravir & Lamivudine	Tablet	Abacavir 600 mg + Dolutegravir 50 mg + Lamivudine 300 mg	SDL
Abiraterone Acetate (Abiranat)	Tablet	250 mg	SDL
Absolute Alcohol	Injection	100%	SDL
Acetazolamide	Tablet	250 mg	SDL
Acetic acid	Ear drops	2%, 3%, 4%, 5%	SDL
Acetylcysteine	Injection	5 g/25 mL	SDL
Aciclovir	Concentrate for infusion	250 mg/10 mL	SDL
Aciclovir	Infusion	250 mg	SDL
Aciclovir	Eye ointment	3%	SDL
Acitretin	Capsule	10 mg, 25 mg	SDL
Adalimumab (Humira)	Prefilled pen	40 mg/0.8 mL	MAF	Checklist to be completed. 1) Treatment of adult patients with rheumatoid arthritis 2) Treatment of adult patients with ankylosing spondylitis 3) Treatment of adult patients with psoriatic arthritis 4) Treatment of juvenile idiopathic arthritis 5) Treatment of adult patients with Crohn's disease 6) Treatment of children (6 years and older) with Crohn's disease 7) Treatment of adult patients with ulcerative colitis 8) Treatment of adult patients with chronic plaque psoriasis 9) Treatment of hidradenitis suppurativa
Adalimumab (Humira)	Prefilled syringe	40 mg/0.8 mL	MAF	Checklist to be completed. 1) Treatment of adult patients with rheumatoid arthritis 2) Treatment of adult patients with ankylosing spondylitis 3) Treatment of adult patients with psoriatic arthritis 4) Treatment of juvenile idiopathic arthritis 5) Treatment of adult patients with Crohn's disease 6) Treatment of children (6 years and older) with Crohn's disease 7) Treatment of adult patients with ulcerative colitis 8) Treatment of adult patients with chronic plaque psoriasis 9) Treatment of hidradenitis suppurativa
Adalimumab Biosimilar (Amgevita)	Prefilled autoinjector	40 mg/0.8 mL	SDL
Adalimumab Biosimilar (Amgevita)	Prefilled syringe	20 mg/0.4 mL, 40 mg/0.8 mL	SDL
Adefovir Dipivoxil	Tablet	10 mg	SDL
Adrenaline	Injection	1:1,000 (1 mg/mL), 1:10,000 (1 mg/10 mL)	SDL
Albendazole	Oral suspension	400 mg/10 mL	SDL
Albendazole	Tablet	400 mg	SDL
Alendronic Acid	Tablet	10 mg, 70 mg	SDL
Alendronic Acid & Colecalciferol	Tablet	Alendronic Acid 70 mg + Colecalciferol 2,800 international units, Alendronic Acid 70 mg + Colecalciferol 5,600 international units	MAF	1) For patients with osteoporosis (T-score ≤ -2.5) 2) For patients with osteopenia (T-score ≤ -1.5) and a history of non-trauma induced fracture
Alfacalcidol	Capsule	0.25 mcg, 1 mcg	SDL
Alfacalcidol	Oral drops	2 mcg/mL	SDL
Alfacalcidol	Tablet	0.25 mcg, 1 mcg	SDL
Alfuzosin Hydrochloride	Tablet	10 mg	SDL
Allopurinol	Tablet	100 mg, 300 mg	SDL
Alteplase	Infusion	50 mg/50 mL	SDL
Aluminium Hydroxide	Tablet	600 mg	SDL
Aluminium Hydroxide, Magnesium Trisilicate & Simeticone	Chewable tablet	Aluminium Hydroxide 250 mg + Magnesium Trisilicate 250 mg + Simeticone 30 mg	SDL
Aluminium Hydroxide, Magnesium Trisilicate & Simeticone	Oral suspension	Aluminium Hydroxide 400 mg/5 mL + Magnesium Trisilicate 400 mg/5 mL + Simeticone 30 mg/5 mL	SDL
Aluminium Oxide	Oral suspension	4%	SDL
Ambrisentan	Tablet	5 mg, 10 mg	MAF	Treatment of adults with a confirmed diagnosis of WHO Functional Class II or III pulmonary arterial hypertension (PAH) who have one of the following PAH aetiologies: • Idiopathic PAH • Heritable or familial PAH • PAH associated with connective tissue disease • Anorexigen-induced PAH • PAH associated with HIV infection
Amikacin	Injection	500 mg/2 mL	SDL
Amiloride & Hydrochlorothiazide	Tablet	Amiloride Hydrochloride 5 mg + Hydrochlorothiazide 50 mg	SDL
Amino Acids	Infusion	5%, 10%	SDL
Aminophylline	Injection	250 mg/10 mL	SDL
Amiodarone Hydrochloride	Injection	50 mg/mL	SDL
Amiodarone Hydrochloride	Tablet	200 mg	SDL
Amitriptyline	Tablet	10 mg, 25 mg	SDL
Amlodipine	Tablet	5 mg, 10 mg	SDL
Amoxicillin	Capsule	250 mg	SDL
Amoxicillin	Oral suspension	125 mg/5 mL, 250 mg/5 mL	SDL
Amoxicillin & Clavulanic Acid	Injection	Amoxicillin 500 mg + Clavulanic Acid 100 mg, Amoxicillin 1 g + Clavulanic Acid 200 mg	SDL
Amoxicillin & Clavulanic Acid	Oral suspension	Amoxicillin 200 mg/5 mL + Clavulanic Acid 28.5 mg/5 mL, Amoxicillin 600 mg/5 mL + Clavulanic Acid 42.9 mg/5 mL	SDL
Amoxicillin & Clavulanic Acid	Tablet	Amoxicillin 500 mg + Clavulanic Acid 125 mg, Amoxicillin 875 mg + Clavulanic Acid 125 mg	SDL
Amphotericin B	Injection	50 mg	SDL
Amphotericin B	Eye drops	1 mg/mL	SDL
Ampicillin	Injection	0.5 g	SDL
Anastrozole	Tablet	1 mg	MAF	Treatment of hormone receptor positive, postmenopausal women with early and advanced breast cancer
Antazoline Hydrochloride & Tetryzoline Hydrochloride	Eye drops	Antazoline Hydrochloride 0.5 mg/mL + Tetryzoline Hydrochloride 0.4 mg/mL	SDL
Anti-Rabies Immunoglubulin	Injection	300 units/2 mL	SDL
Apixaban	Tablet	2.5 mg, 5 mg	MAF	1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)* and CHA₂DS₂-VASc score of 1 or more for men, and 2 or more for women *This excludes patients with rheumatic mitral stenosis or prosthetic heart valves 2) Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE in adults. MAF assistance does not apply to patients with isolated distal DVT
Aprepitant	Capsule	80 mg	MAF	Prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
Aprepitant	Capsule	80 mg & 125 mg (Tripack)	MAF	Prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
Aqueous Cream	Cream	Emulsifying Ointment 30% with either Chlorocresol 0.1% or Phenoxyethanol 0.1%	SDL
Ascorbic Acid	Tablet	100 mg	SDL
Ascorbic Acid	Injection	1 g/20 mL, 500 mg/5 mL	SDL
Aspirin	Tablet	100 mg, 300 mg	SDL
Atazanavir	Capsule	200 mg, 300 mg	SDL
Atenolol	Tablet	50 mg, 100 mg	SDL
Atorvastatin	Tablet	10 mg, 20 mg, 40 mg, 80 mg	SDL
Atracurium	Injection	25 mg/2.5 mL, 50 mg/5 mL	SDL
Atropine Sulfate	Eye drops	0.5%, 1%	SDL
Atropine Sulfate	Injection	0.6 mg/mL	SDL
Azathioprine	Tablet	25 mg, 50 mg	SDL
Azithromycin	Extended-release oral suspension	2 g	SDL
Azithromycin	Injection	500 mg	SDL
Azithromycin	Oral suspension	200 mg/5 mL	SDL
Azithromycin	Tablet	250 mg	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Bacillus Calmette-Guerin	Solution for intravesical use	12.5 mg, 40 mg, 80 mg	SDL
Bacillus Calmette-Guerin Vaccine	Injection	0.75 mg/mL	SDL
Beclomethasone	Inhaler	250 mcg/dose	SDL
Beclomethasone Dipropionate	Inhaler	50 mcg/dose	SDL
Benzalkonium Chloride & Cetrimide	Cream	Benzalkonium Chloride 0.01% + Cetrimide 0.2%	SDL
Benzathine Benzylpenicillin	Injection	2.4 million international units	SDL
Benztropine	Injection	2 mg/2 mL	SDL
Benztropine Mesilate	Tablet	2 mg	SDL
Benzhexol Hydrochloride	Tablet	2 mg	SDL
Benzoyl Peroxide	Gel	2.5%, 5%, 10%	SDL
Benzoyl Peroxide	Lotion	5%, 10%	SDL
Benzyl Benzoate	Topical emulsion	25%	SDL
Benzylpenicillin Sodium	Eye drops (preservative-free)	2,500 international units/mL	SDL
Benzylpenicillin Sodium	Injection	1 million international units, 5 million international units	SDL
Betaine	Powder	180 g	MAF	1) Treatment of classic homocysteinuria 2) Treatment of homocysteinuria secondary to sulfite oxidase deficiency, methionine synthase deficiency or cobalamin-related remethylation pathway defect
Betahistine Mesilate	Tablet	6 mg	SDL
Betamethasone (as Valerate)	Scalp lotion	0.1%	SDL
Betamethasone (as Valerate)	Cream	0.0125%, 0.025%, 0.05%, 0.1%	SDL
Betamethasone (as Valerate)	Ointment	0.025%, 0.05%, 0.1%	SDL
Betamethasone (as Valerate) & Clioquinol	Cream	Betamethasone 0.025% + Clioquinol 3%, Betamethasone 0.05% + Clioquinol 3%, Betamethasone 0.1% + Clioquinol 3%	SDL
Betamethasone Sodium Phosphate	Eye/ear drops	0.1%	SDL
Betamethasone Sodium Phosphate	Eye/ear drops	0.1%	SDL
Betaxolol	Eye drops	0.25%	SDL
Bethanechol Chloride	Tablet	10 mg	SDL
Bevacizumab	Intravitreal injection	25 mg/mL	MAF	1) Treatment of adults with visual impairment due to neovascular (wet) age-related macular degeneration 2) Treatment of adults with visual impairment due to macular oedema secondary to central or branch retinal vein occlusion 3) Treatment of adults with visual impairment due to diabetic macular oedema
Bisacodyl	Enteric-coated tablet	5 mg	SDL
Bisacodyl	Rectal suppository	10 mg	SDL
Bismuth Subcitrate	Tablet	120 mg	SDL
Bismuth Subgallate	Rectal suppository	Bismuth Subgallate 200 mg + Zinc Oxide 120 mg	SDL
Bismuth Subsalicylate	Tablet	262.5 mg	SDL
Bisoprolol Fumarate	Tablet	2.5 mg, 5 mg	SDL
Bleomycin	Injection	15,000 international units (USP 15 units)	SDL
Blinatumomab	Infusion	35 mg	MAF	Treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL) for a maximum of 2 cycles for induction in a lifetime. Patients with Philadelphia chromosome positive disease must have previously received a tyrosine kinase inhibitor. Patients who achieve a complete response after induction can receive up to three additional cycles for consolidation in a lifetime. Complete response is defined as a patient who: a) has 5% or less bone marrow blasts; and b) has no evidence of disease; and c) has platelet count of more than 50,000 per microlitre; and d) has absolute neutrophil count of more than 500 per microlitre.
Boric Acid, Resorcinol & Phenol	Paint	Boric Acid 0.8% + Resorcinol 8% + Phenol 4%	SDL
Bortezomib	Injection	3.5 mg	MAF	Checklist to be completed. For primary induction in newly diagnosed patients with symptomatic multiple myeloma
Botulinum toxin type A complex (Botox)	Injection	50 units, 100 units	MAF	1) For adults with focal spasticity of the upper limbs due to stroke, who have Modified Ashworth Scale of 2 or more at the target muscle intended for botulinum toxin A treatment, and do not have the affected joint permanently fixed in position due to fibrotic shortening of the target muscle and are concurrently receiving physiotherapy 2) For adults with cervical dystonia, blepharospasm or hemifacial spasm 3) For children aged 2 years or older, with focal spasticity of the upper or lower limbs (including dynamic equinus foot deformity) due to cerebral palsy, and who do not have significant joint contractures (i.e. the affected joint is not permanently fixed in position due to shortening of the target muscle); and are concurrently receiving supportive therapy (e.g. physiotherapy or occupational therapy)
Brimonidine Tartrate	Eye drops	0.15%	SDL
Bromocriptine	Tablet	2.5 mg	SDL
Buclizine Hydrochloride	Tablet	25 mg	SDL
Budesonide	Powder inhaler	100 mcg/dose, 200 mcg/dose	SDL
Bupivacaine Hydrochloride (hyperbaric)	Injection	0.5% (in dextrose 8%)	SDL
Bupivacaine Hydrochloride (isobaric)	Injection	0.5%	SDL
Buprenorphine	Sublingual tablet	0.2 mg	SDL
Busulfan	Injection	60 mg	SDL
Busulfan	Tablet	2 mg	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
C1 Esterase Inhibitor (Human)	Injection	500 international units/10 mL	MAF	Treatment of hereditary angioedema
Cabergoline	Tablet	0.5 mg	MAF	As a 2nd line agent for the management of hyperprolactinaemia in patients who have failed to respond or who are unable to tolerate bromocriptine
Calamine	Lotion	Calamine 15%	SDL
Calamine & Menthol	Lotion	Calamine 15% + Menthol 0.4%	SDL
Calcipotriol	Ointment	50 mcg/g	SDL
Calcipotriol	Scalp solution	50 mcg/mL	SDL
Calcipotriol & Betamethasone	Gel	Calcipotriol 50 mcg/g + Betamethasone (as Diproprionate) 0.5 mg/g	SDL
Calcipotriol & Betamethasone	Ointment	Calcipotriol 50 mcg/g + Betamethasone (as Diproprionate) 0.5 mg/g	SDL
Calcitriol	Capsule	0.25 mcg, 0.5 mcg	SDL
Calcium	Syrup	20 mg to 23 mg Ca2+/mL	SDL
Calcium Acetate	Tablet	667 mg	SDL
Calcium Carbonate	Chewable tablet	1.25 g	SDL
Calcium Carbonate	Tablet	625 mg	SDL
Calcium Carbonate & Colecalciferol	Tablet	Calcium Carbonate 450 mg + Colecalciferol 5 mcg	SDL
Calcium Chloride Dihydrate	Injection	10%	SDL
Calcium Gluconate	Injection	10%	SDL
Calf Blood Extract (deproteinised)	Eye gel	8.3 mg/g	SDL
Calfactant	Intratracheal suspension	105 mg/3 mL, 210 mg/6 mL	SDL
Candesartan Cilexetil	Tablet	4 mg, 8 mg, 16 mg	MAF	Treatment of patients with heart failure who cannot tolerate angiotensin converting enzyme inhibitors
Capecitabine	Tablet	150 mg, 500 mg	SDL
Captopril	Tablet	12.5 mg, 25 mg	SDL
Carbamazepine	Controlled-release tablet	200 mg, 400 mg	SDL
Carbamazepine	Syrup	100 mg/5 mL	SDL
Carbamazepine	Tablet	200 mg	SDL
Carbimazole	Tablet	5 mg	SDL
Carboplatin	Injection	150 mg/mL, 10 mg/mL	SDL
Carmustine	Injection	100 mg	SDL
Carvedilol	Tablet	6.25 mg, 12.5 mg, 25 mg	SDL
Cefalexin	Capsule	250 mg	SDL
Cefalexin	Oral suspension	125 mg/5 mL	SDL
Cefazolin	Injection	1 g	SDL
Ceftazidime	Injection	1 g	SDL
Ceftriaxone	Injection	250 mg, 1 g, 2 g	SDL
Celecoxib	Capsule	200 mg	SDL
Cetirizine	Solution	1 mg/mL	SDL
Cetrimide	Topical solution	1%	SDL
Cetrimide	Shampoo	5%	SDL
Charcoal (activated)	Capsule	200 mg	SDL
Charcoal (activated)	Granules	50 g	SDL
Charcoal (activated)	Oral suspension	200 mg/mL (in sorbitol 70%)	SDL
Charcoal (activated)	Tablet	200 mg, 250 mg	SDL
Chloral Hydrate	Oral solution	200 mg/5 mL, 500 mg/5 mL	SDL
Chlorambucil	Tablet	2 mg	SDL
Chloramphenicol	Eye drops	0.5%	SDL
Chloramphenicol	Eye ointment	1%	SDL
Chlordiazepoxide	Tablet	5 mg	SDL
Chlorhexidine Gluconate	Cream	1%	SDL
Chlorhexidine Salt	Mouthwash	0.2%	SDL
Chlorhexidine Salt	Topical solution	0.05%, 0.1%	SDL
Chlorhexidine Salt	Topical solution	4%	SDL
Chlorhexidine Salt	Mouthwash	0.2%	SDL
Chlorhexidine Salt & Alcohol	Topical solution	Chlorhexidine Salt 0.1% + Alcohol 70%, Chlorhexidine Salt 0.5% + Alcohol 70%	SDL
Chlorhexidine Salt & Cetrimide	Topical solution	Chlorhexidine Salt 0.015% + Cetrimide 0.15%	SDL
Chloroquine Phosphate	Tablet	150 mg	SDL
Chlorpheniramine	Syrup	4 mg/5 mL	SDL
Chlorpheniramine	Tablet	4 mg	SDL
Chlorpromazine	Injection	50 mg/2 mL	SDL
Chlorpromazine	Tablet	25 mg, 100 mg	SDL
Chlorpropamide	Tablet	250 mg	SDL
Chlortetracycline	Eye ointment	1%	SDL
Choline Salicylate & Cetylpyridinium Chloride	Oral gel	Choline Salicylate 8.7% + Cetylpyridinium Chloride 0.01%	SDL
Ciclosporin	Capsule	10 mg, 25 mg, 100 mg	SDL
Ciclosporin	Concentrate for infusion	50 mg/mL	SDL
Ciclosporin	Oral solution	100 mg/mL	SDL
Cimetidine	Injection	200 mg/2 mL, 150 mg/mL	SDL
Cimetidine	Tablet	200 mg	SDL
Ciprofloxacin	Tablet	250 mg, 500 mg	SDL
Ciprofloxacin	Eye/ear drops	0.3%	SDL
Ciprofloxacin	Infusion	2 mg/mL	SDL
Cisplatin	Concentrate for infusion	50 mg/50 mL	SDL
Citric Acid Monohydrate & Potassium Citrate	Oral solution	Citric Acid Monohydrate 0.25 g/5 mL + Potassium Citrate 1.5 g/5 mL	SDL
Clarithromycin	Modified-release tablet	500 mg	SDL
Clarithromycin	Tablet	250 mg, 500 mg	SDL
Clarithromycin	Injection	500 mg	SDL
Clarithromycin	Oral suspension	125 mg/5 mL	SDL
Clidinium & Chlordiazepoxide	Tablet	Clidinium Bromide 2.5 mg + Chlordiazepoxide 5 mg	SDL
Clindamycin	Capsule	150 mg	SDL
Clindamycin	Injection	150 mg/mL	SDL
Clomiphene	Tablet	50 mg	SDL
Clomipramine	Tablet	25 mg	SDL
Clonazepam	Tablet	0.5 mg, 2 mg	SDL
Clopidogrel	Tablet	75 mg	SDL
Clotrimazole	Cream	1%	SDL
Clotrimazole	Lotion	1%	SDL
Clotrimazole	Powder	1%	SDL
Clotrimazole	Vaginal tablet	100 mg	SDL
Cloxacillin	Capsule	250 mg	SDL
Cloxacillin	Injection	250 mg, 500 mg	SDL
Cloxacillin	Syrup	125 mg/5 mL	SDL
Clozapine	Tablet	25 mg, 100 mg	SDL
Coal Tar	Cream	5%, 10%, 15%	SDL
Coal Tar	Lotion	20%	SDL
Coal Tar	Shampoo	25%	SDL
Coal Tar & Salicylic Acid	Ointment	Coal Tar 5% + Salicylic acid 2%	SDL
Cocaine	Solution	10%	SDL
Cocois Compound	Ointment	Coal Tar Solution 10% + Camphor 2% + Sulphur 4% + Salicylic Acid 2%	SDL
Codeine & Promethazine	Syrup	Codeine Phosphate 18 mg/10 mL + Promethazine 7.2 mg/10 mL	SDL
Codeine Phosphate	Tablet	30 mg	SDL
Coenzyme Q10	Capsule	50 mg	MAF	Treatment of mitochondrial disorders
Colchicine	Tablet	500 mcg	SDL
Colecalciferol	Tablet	1,000 units	SDL
Colestyramine	Powder for oral suspension	4 g	SDL
Compound Diphenhydramine	Syrup	Ranging from 5 mg/5 mL to 14 mg/5 mL	SDL
Compound Polyethylene Glycol (Fortrans)	Oral powder	-	SDL
Compound Sodium Lactate	Infusion	-	SDL
Conjugated Oestrogens	Tablet	0.3 mg, 0.625 mg	SDL
Conjugated Oestrogens	Vaginal cream	0.625 mg/g	SDL
Cyanocobalamin	Injection	1 mg/mL	SDL
Cyclophosphamide	Infusion	200 mg, 1 g	SDL
Cyclophosphamide	Tablet	50 mg	SDL
Cyproheptadine	Tablet	4 mg	SDL
Cytarabine	Injection	20 mg/mL, 100 mg/mL	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Dacarbazine	Injection	200 mg	SDL
Dactinomycin	Infusion	500 mcg	SDL
Dantrolene Sodium	Capsule	25 mg, 100 mg	SDL
Dapagliflozin	Tablet	5 mg, 10 mg	MAF	1) Treatment of type 2 diabetes mellitus, as a dual therapy • In combination with metformin for patients with HbA1c > 7% despite treatment with metformin monotherapy; • In combination with a sulfonylurea for patients with HbA1c > 7% despite treatment with sulfonylurea monotherapy and when metformin is contraindicated or not tolerated; 2) Treatment of type 2 diabetes mellitus as a triple therapy • In combination with metformin and a sulfonylurea for patients with HbA1c > 7% despite treatment with optimal doses of dual therapy 3) Treatment of type 2 diabetes mellitus in combination with insulin, with or without metformin
Dapsone	Tablet	100 mg	SDL
Darunavir	Tablet	600 mg, 800 mg	SDL
Daunorubicin	Injection	20 mg	SDL
Deferiprone	Oral solution	100 mg/mL	SDL
Deferiprone	Tablet	500 mg	SDL
Deferoxamine Mesilate	Injection	500 mg	SDL
Denosumab	Prefilled syringe	60 mg/mL	MAF	Treatment of post-menopausal women with osteoporosis (T-score ≤ -2.5) at high risk of fracture and eGFR > 30 mL/min and who are unable to tolerate or follow the administration instructions for oral bisphosphonates
Dequalinium Chloride	Lozenge	0.25 mg	SDL
Desmopressin Acetate	Nasal drops	0.1 mg/mL	SDL
Desmopressin Acetate	Nasal spray	10 mcg/dose	SDL
Desmopressin Acetate	Tablet	0.1 mg, 0.2 mg	SDL
Dexamethasone	Tablet	500 mcg, 4 mg	SDL
Dexamethasone Phosphate	Injection	4 mg/mL	SDL
Dexmedetomidine	Concentrate for infusion	200 mcg/2 mL	SDL
Dextromethorphan Hydrobromide	Syrup	15 mg/5 mL	SDL
Dextromethorphan Hydrobromide	Tablet	15 mg	SDL
Dextrose & Potassium Chloride	Infusion	Dextrose 5% + Potassium Chloride 0.15%	SDL
Dextrose & Sodium Chloride	Infusion	Dextrose 2.5% + Sodium Chloride 0.45%, Dextrose 5% + Sodium Chloride 0.2%, Dextrose 5% + Sodium Chloride 0.45%, Dextrose 5% + Sodium Chloride 0.9%	SDL
Dextrose Monohydrate	Infusion	5%, 10%, 20%, 50%	SDL
Dextrose Monohydrate	Injection	50%	SDL
Dextrose, Potassium Chloride & Sodium Chloride	Infusion	Dextrose 5% + Potassium Chloride 0.15% + Sodium Chloride 0.33%, Dextrose 5% + Potassium Chloride 0.22% + Sodium Chloride 0.45%, Dextrose 5% + Potassium Chloride 0.30% + Sodium Chloride 0.45%, Dextrose 5% + Potassium Chloride 0.15% + Sodium Chloride 0.45%, Dextrose 5% + Potassium Chloride 0.15% + Sodium Chloride 0.9%	SDL
Diazepam	Enema	5 mg/2.5 mL	SDL
Diazepam	Injection	5 mg/mL	SDL
Diazepam	Tablet	2 mg, 5 mg, 10 mg	SDL
Dibasic Sodium Phosphate & Monobasic Sodium Phosphate	Enema	Dibasic Sodium Phosphate 7 g/118 mL + Monobasic Sodium Phosphate 19 g/118 mL, Dibasic Sodium Phosphate 3.5 g/59 mL + Monobasic Sodium Phosphate 9.5 g/59 mL	SDL
Diclofenac Sodium	Enteric-coated tablet	25 mg, 50 mg	SDL
Diclofenac Sodium	Injection	25 mg/mL	SDL
Diclofenac Sodium	Rectal suppository	12.5 mg, 25 mg, 50 mg	SDL
Diclofenac Sodium	Gel	1%	SDL
Diethylcarbamazine Citrate	Tablet	50 mg	SDL
Digoxin	Injection	100 mcg/mL, 250 mcg/mL	SDL
Digoxin	Oral solution	50 mcg/mL	SDL
Digoxin	Tablet	62.5 mcg, 250 mcg	SDL
Digoxin-specific Antibody Fragments	Injection	40 mg	SDL
Diltiazem Hydrochloride	Injection	10 mg, 50 mg	SDL
Diltiazem Hydrochloride	Sustained-release capsule	90 mg, 100 mg, 200 mg	SDL
Diltiazem Hydrochloride	Tablet	30 mg, 60 mg	SDL
Dimercaprol	Injection	50 mg/mL	SDL
Diosmin & Hesperidin	Tablet	Diosmin 450 mg + Hesperidin 50 mg	SDL
Diphenoxylate & Atropine Sulfate	Tablet	Diphenoxylate Hydrochloride 2.5 mg + Atropine Sulfate 25 mcg	SDL
Diphtheria & Tetanus Vaccine	Injection	Diphtheria Toxoid Vaccine minimum 2 international units/0.5 mL + Tetanus Toxoid Vaccine minimum 20 international units/0.5 mL	SDL
Diphtheria Antitoxin	Injection	10,000 units	SDL
Diphtheria, Tetanus & Pertussis Vaccine	Injection	Diphtheria Toxoid Vaccine minimum 30 international units/0.5 mL + Tetanus Toxoid Vaccine minimum 40 international units/0.5 mL + Pertussis Toxoid Vaccine 25 microgram/0.5 mL + Filamentous Haemagglutinin 25 microgram/0.5 mL + Pertactin 8 microgram/0.5 mL	SDL
Dipyridamole	Tablet	25 mg, 75 mg	SDL
Disodium Edetate	Eye drops	0.38%, 3%	SDL
Dobutamine	Concentrate for infusion	250 mg/5 mL, 250 mg/20 mL	SDL
Docetaxel	Infusion	20 mg, 80 mg, 160 mg	MAF	1) For the treatment of patients with locally advanced or metastatic breast cancer. 2) In combination with doxorubicin and cyclophosphamide for the adjuvant treatment of patients with operable node-positive or operable node-negative breast cancer. 3) For the treatment of patients with locally advanced or metastatic non-small cell lung cancer. 4) In combination with prednisone or prednisolone for the treatment of patients with hormone refractory metastatic prostate cancer.
Donepezil Hydrochloride	Oral disintegrating tablet	5 mg, 10 mg	MAF	For patients with mild to moderately severe Alzheimer's Disease who have swallowing difficulties and are unable to receive a film-coated tablet
Donepezil Hydrochloride	Tablet	5 mg, 10 mg	SDL
Dopamine Hydrochloride	Concentrate for infusion	200 mg/5 mL	SDL
Dolutegravir	Tablet	50 mg	SDL
Dothiepin Hydrochloride	Capsule	25 mg	SDL
Doxorubicin Hydrochloride	Injection	10 mg, 50 mg	SDL
Doxycycline	Capsule	100 mg	SDL
Droperidol	Injection	2.5 mg/mL	SDL
Dutasteride	Capsule	0.5 mg	SDL
Dydrogesterone	Tablet	10 mg	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Efavirenz	Tablet	200 mg, 600 mg	SDL
Empagliflozin	Tablet	10 mg, 25 mg	MAF	1) Treatment of type 2 diabetes mellitus, as a dual therapy • In combination with metformin for patients with HbA1c > 7% despite treatment with metformin monotherapy; • In combination with a sulfonylurea for patients with HbA1c > 7% despite treatment with sulfonylurea monotherapy and when metformin is contraindicated or not tolerated; 2) Treatment of type 2 diabetes mellitus as a triple therapy • In combination with metformin and a sulfonylurea for patients with HbA1c > 7% despite treatment with optimal doses of dual therapy 3) Treatment of type 2 diabetes mellitus in combination with insulin, with or without metformin
Emtricitabine & Tenofovir Disoproxil Fumarate	Tablet	Emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg	MAF	In combination with other antiretroviral agents for the treatment of HIV-1 infection
Emulsifying Ointment	Ointment	-	SDL
Enalapril Maleate	Tablet	5 mg, 10 mg, 20 mg	SDL
Enoxaparin Sodium	Injection	20 mg/0.2 mL, 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL	SDL
Entacapone	Tablet	200 mg	SDL
Entecavir	Tablet	0.5 mg, 1 mg	MAF	Treatment of nucleos(t)ide-naïve patients with HBeAg-positive and HBeAg-negative chronic hepatitis B infection and evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease
Ephedrine Sulfate	Injection	30 mg/mL	SDL
Epoetin Alfa	Injection	2,000 international units/0.5 mL, 4,000 international units/0.4 mL	SDL
Epoetin Beta	Injection	2,000 international units/0.3 mL, 4,000 international units/0.3 mL	SDL
Epoprostenol (Veletri)	Infusion	1.5 mg	MAF	Treatment of pulmonary arterial hypertension (idiopathic or heritable PAH or PAH associated with connective tissue diseases) in patients with WHO Functional Class III-IV symptoms
Ergometrine Maleate	Injection	500 mcg/mL	SDL
Ergotamine & Caffeine	Tablet	Caffeine 100 mg + Ergotamine Tartrate 1 mg	SDL
Erythromycin (as Ethyl Succinate)	Tablet	400 mg	SDL
Erythromycin (as Ethyl Succinate)	Oral suspension	200 mg/5 mL	SDL
Erythromycin (as Lactobionate)	Infusion	500 mg, 1 g	SDL
Erythromycin Stearate	Enteric-coated tablet	250 mg	SDL
Estradiol	Vaginal tablet	10 mcg	SDL
Etanercept	Prefilled syringe	25 mg/0.5 mL, 50 mg/mL	MAF	Checklist to be completed 1) Treatment of adult patients with non-radiographic axial spondyloarthritis 2) Treatment of juvenile idiopathic arthritis 3) Treatment of adult patients with chronic plaque psoriasis
Etanercept	Injection	25 mg/mL	MAF	Checklist to be completed 1) Treatment of adult patients with non-radiographic axial spondyloarthritis 2) Treatment of juvenile idiopathic arthritis 3) Treatment of adult patients with chronic plaque psoriasis
Ethambutol Hydrochloride	Tablet	100 mg, 400 mg	SDL
Ethanol	Solution	Minimum 95%	SDL
Ethionamide	Tablet	250 mg	SDL
Ethyl Chloride	Topical spray	88 g/100 mL	SDL
Etoposide	Capsule	50 mg	SDL
Etoposide	Concentrate for infusion	20 mg/mL	SDL
Etoricoxib	Tablet	60 mg, 90 mg, 120 mg	SDL
Etravirine	Tablet	200 mg	SDL
Everolimus	Tablet	0.25 mg, 0.75 mg	SDL
Ezetimibe	Tablet	10 mg	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class
Factor Eight Inhibitor Bypassing Activity (FEIBA)	Injection	500 units	SDL
Famotidine	Tablet	20 mg	SDL
Fenofibrate	Capsule	100 mg, 300 mg	SDL
Fentanyl	Injection	50 mcg/mL	SDL
Fentanyl	Transdermal patch	12 mcg/hr, 25 mcg/hr, 50 mcg/hr	SDL
Ferric Carboxymaltose	Injection	500 mg/10 mL	SDL
Ferrous Fumarate	Tablet	200 mg	SDL
Ferrous Gluconate	Tablet	300 mg	SDL
Ferrous Gluconate, Multivitamins & Minerals	Capsule	Ferrous Gluconate 250 mg + Vit B12 7.5 mcg + Vit C 50 mg + Folic Acid 1 mg + Sorbitol 25 mg + Copper Sulfate 200 mcg + Manganese Sulfate 200 mcg	SDL
Ferrous Sulphate & Vitamin B1 & Riboflavin & Nicotinamide	Tablet	Ferrous Sulphate 200 mg + Vitamin B1 3 mg + Riboflavin 1.5 mg + Nicotinamide 10 mg	SDL
Filgrastim	Injection	30 million units/0.5 mL (300 mcg/0.5 mL), 30 million units/mL (300 mcg/mL)	SDL
Finasteride	Tablet	5 mg	SDL
Fluconazole	Capsule	50 mg, 100 mg, 150 mg	SDL
Fluconazole	Infusion	100 mg/50 mL	SDL
Fludrocortisone Acetate	Tablet	0.1 mg	SDL
Flumazenil	Injection	0.1 mg/mL	SDL
Fluocinolone Acetonide	Cream	0.003125%, 0.00625%, 0.0125%, 0.025%	SDL
Fluorescein Sodium	Injection	10%	SDL
Fluorescein Sodium	Single-use eye drops	2%	SDL
Fluorouracil	Injection	50 mg/mL	SDL
Fluoxetine	Capsule	10 mg, 20 mg	SDL
Flupenthixol Decanoate	Injection	20 mg/mL, 40 mg/2 mL	SDL
Fluphenazine Decanoate	Injection	25 mg/mL	SDL
Fluticasone Propionate	Inhaler	50 mcg/dose, 125 mcg/dose, 250 mcg/dose	SDL
Fluvoxamine Maleate	Tablet	50 mg	SDL
Folic Acid	Tablet	5 mg	SDL
Folinic Acid	Injection	10 mg/mL	SDL
Formoterol & Budesonide	Inhaler	Formoterol Fumarate Dihydrate 2.25 mcg/dose + Budesonide 80 mcg/dose (120 doses), Formoterol Fumarate Dihydrate 4.5 mcg/dose + Budesonide 80 mcg/dose (120 doses), Formoterol Fumarate Dihydrate 4.5 mcg/dose + Budesonide 160 mcg/dose (120 doses)	SDL
Formoterol & Budesonide	Powder inhaler	Formoterol Fumarate Dihydrate 4.5 mcg/dose + Budesonide 80 mcg/dose (60 doses), Formoterol Fumarate Dihydrate 4.5 mcg/dose + Budesonide 160 mcg/dose (120 doses), Formoterol Fumarate Dihydrate 9 mcg/dose + Budesonide 320 mcg/dose (60 doses)	SDL
Furosemide	Injection	10 mg/mL	SDL
Furosemide	Tablet	40 mg	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Gabapentin	Capsule	100 mg, 300 mg, 400 mg	SDL
Ganciclovir	Infusion	500 mg	SDL
Gelatin Succinylated & Sodium Chloride	Infusion	Gelatin Succinylated 4 g/100 mL + Sodium Chloride 0.701 g/100 mL	SDL
Gemcitabine	Infusion	200 mg, 1000 mg, 2000 mg	SDL
Gemfibrozil	Capsule	300 mg	SDL
Gentamicin	Injection	40 mg/mL	SDL
Gentamicin	Eye drops	0.3%	SDL
Gentian Violet	Paint	0.5%	SDL
Glecaprevir & Pibrentasvir	Tablet	Glecaprevir 100 mg + pibrentasvir 40 mg tablet	MAF	Treatment of chronic hepatitis C (all genotypes) infection in treatment-naïve, pegylated interferon plus ribavirin (with or without sofosbuvir)-experienced and sofosbuvir plus ribavirin-experienced adults. Glecaprevir/Pibrentasvir should be used in line with the recommended treatment regimen and duration: Treatment-naive • 8 weeks’ treatment of glecaprevir/pibrentasvir for patients with hepatitis C virus (all genotypes) without cirrhosis or compensated cirrhosis (Child-Pugh A); Treatment-experienced • 8 weeks’ treatment of glecaprevir/pibrentasvir for patients with hepatitis C virus (genotypes 1,2,4,5,6) without cirrhosis • 12 weeks’ treatment of glecaprevir/pibrentasvir for patients with hepatitis C virus (genotypes 1,2,4,5,6) with compensated cirrhosis (Child-Pugh A) • 16 weeks’ treatment of glecaprevir/pibrentasvir for patients with hepatitis C virus (genotype 3) without cirrhosis or with compensated cirrhosis (Child-Pugh A)
Glibenclamide	Tablet	5 mg	SDL
Gliclazide	Tablet	80 mg	SDL
Glipizide	Tablet	5 mg	SDL
Glucagon	Injection	1 mg	SDL
Glycerol	Rectal suppository	1 g, 1.5 g, 2 g	SDL
Glycerol, Methyl Salicylate, Sodium Salicylate & Thymol Compound	Mouthwash	Glycerol 10% + Methyl Salicylate 0.03% + Sodium Salicylate 0.52% + Thymol 0.05%	SDL
Glyceryl Trinitrate	Oral spray	0.4 mg/dose	SDL
Glyceryl Trinitrate	Patch	5 mg, 10 mg	SDL
Glyceryl Trinitrate	Sublingual tablet	0.5 mg	SDL
Glycine	Irrigation solution	1.5%	SDL
Golimumab	Prefilled syringe	50 mg/0.5 mL	MAF	Checklist to be completed 1) Treatment of adult patients with rheumatoid arthritis 2) Treatment of adult patients with ankylosing spondylitis 3) Treatment of adult patients with psoriatic arthritis 4) Treatment of adult patients with non-radiographic axial spondyloarthritis 5) Treatment of adult patients with ulcerative colitis
Goserelin	Subcutaneous injectable implant	3.6 mg, 10.8 mg	MAF	LHRH agonist is recommended: 1) As primary therapy for men with locally advanced or metastatic prostate cancer 2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy 3) For men with prostate cancer who have a biochemical relapse LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer
Griseofulvin	Tablet	125 mg, 500 mg	SDL
Guaifenesin	Syrup	100 mg/5 mL	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Haemodialysis Concentrate 35X (Acetate Salt)	Solution	The diluted solution contains: Na+ 140.0 mmol/L, K+ 2.60 mmol/L, Ca2+ 1.38 mmol/L, Mg2+ 0.62 mmol/L, Cl- 102 mmol/L, HCO3- 45 mmol/L	SDL
Haemodialysis Concentrate 35X (Bicarbonate)	Solution (comprised 2 separate 10 L canisters: acidic & basic)	Acidic concentrate: KCl 5.5 g/L, NaCl 161.0 g/L, CaCl2.2H2O 9.7 g/L, MgCl2.6H2O 3.7 g/L, CH3COOH (glacial) 8.8 g/L; Basic concentrate: NaCl 30.5 g/L, HCO3- 66.0 g/L; Final diluted solution contains: Na+ 140 mmol/L, K+ 2.0 mmol/L, Ca2+ 1.8 mmol/L, Mg2+ 0.5 mmol/L, Cl- 107.2 mmol/L, CH3COO- 4.0 mmol/L, HCO3- 35.0 mmol/L	SDL
Haloperidol	Injection	5 mg/mL	SDL
Haloperidol	Oral solution	2 mg/mL	SDL
Haloperidol	Tablet	0.5 mg, 1.5 mg, 5 mg	SDL
Heparin Sodium	Injection	1,000 units/mL, 5,000 units/mL, 25,000 units/5 mL	SDL
Heparinised Saline	Injection (in sodium chloride 0.9%, preservative-free)	50 international units/5 mL	SDL
Hepatitis B Immunoglobulin	Injection	≥ 200 international units/mL (adults), ≥100 international units/mL (children)	SDL
Homatropine Hydrobromide	Eye drops	2%	SDL
Human Hemin	Infusion	250 mg/10 mL	MAF	Treatment of acute attacks of hepatic porphyria (acute intermittent porphyria, porphyria variegata, hereditary coproporphyria)
Hydralazine Hydrochloride	Tablet	10 mg, 25 mg, 50 mg	SDL
Hydralazine Hydrochloride	Injection	20 mg/mL	SDL
Hydrochlorothiazide	Tablet	25 mg	SDL
Hydrocolloid (carboxymethylcellulose-containing)	Dressing	-	SDL
Hydrocolloid (carboxymethylcellulose-containing)	Gel	-	SDL
Hydrocortisone	Cream	0.5%, 1%	SDL
Hydrocortisone	Ointment	1%	SDL
Hydrocortisone	Tablet	10 mg	SDL
Hydrocortisone (as Sodium Succinate)	Injection	100 mg	SDL
Hydrocortisone Acetate	Rectal foam	10%	SDL
Hydrocortisone Acetate & Clioquinol	Cream	Hydrocortisone Acetate 1% + Clioquinol 3%	SDL
Hydrogen Peroxide	Mouthwash	3%	SDL
Hydrogen Peroxide	Topical solution	3%	SDL
Hydroxocobalamin	Injection	1 mg/mL	MAF	Treatment of cobalamin-related remethylation pathway defect causing cobalamin C deficiency
Hydroxychloroquine Sulphate	Tablet	200 mg	SDL
Hydroxychloroquine Sulphate	Tablet	200 mg	SDL
Hydroxyprogesterone Caporate	Injection	250 mg/mL	SDL
Hydroxyurea	Capsule	500 mg	SDL
Hydroxyzine Hydrochloride	Tablet	10 mg, 25 mg	SDL
Hydroxyzine Hydrochloride	Syrup	10 mg/5 mL	SDL
Hyoscine Butylbromide	Injection	20 mg/mL	SDL
Hyoscine Butylbromide	Tablet	10 mg	SDL
Hyoscine Hydrobromide Trihydrate	Injection	400 mcg/mL	SDL
Hypromellose	Eye drops	0.3%	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Ibuprofen	Oral liquid	100 mg/5 mL	SDL
Ibuprofen	Tablet	200 mg	SDL
Ifosfamide	Infusion	1 g	SDL
Imatinib (Generic)*	Capsule	100 mg, 400 mg	SDL	*Generic formulation cannot be used for gastrointestinal stromal tumours (GIST) due to patent protection
Imatinib (Generic)*	Tablet	100 mg, 400 mg	SDL	*Generic formulation cannot be used for gastrointestinal stromal tumours (GIST) due to patent protection
Imipenem & Cilastatin	Infusion	Imipenem 500 mg + Cilastatin 500 mg	SDL
Imipramine Hydrochloride	Tablet	10 mg, 25 mg	SDL
Indometacin	Capsule	25 mg	SDL
Infliximab (Remsima)	Infusion	100 mg	MAF	Checklist to be completed 1) Treatment of adult patients with rheumatoid arthritis 2) Treatment of adult patients with ankylosing spondylitis 3) Treatment of adult patients with psoriatic arthritis 4) Treatment of adult patients with Crohn's disease 5) Treatment of children (6 to 17 years) with Crohn's disease 6) Treatment of adult patients with ulcerative colitis 7) Treatment of children (6 to 17 years) with ulcerative colitis 8) Treatment of adult patients with chronic plaque psoriasis
Insulin Aspart	Injection, penfill	100 international units/mL	MAF	Type 1 & 2 diabetes mellitus
Insulin Aspart	Injection, prefilled pen	100 international units/mL	SDL
Insulin Aspart & Insulin Aspart Protamine	Injection, prefilled pen	Insulin Aspart 30% + Insulin Aspart Protamine 70%	SDL
Insulin Detemir	Injection, prefilled pen	100 international units/mL	SDL
Insulin Glargine (Basaglar)	Injection, cartridge	100 international units/mL	SDL
Insulin Glargine (Lantus)	Injection	100 international units/mL	SDL
Insulin Glargine (Lantus)	Injection, prefilled pen	100 international units/mL	SDL
Insulin Glulisine	Injection, prefilled pen	100 international units/mL	SDL
Insulin Isophane (Human)	Injection	100 international units/mL	SDL
Insulin Isophane (Human)	Injection, penfill	100 international units/mL	SDL
Insulin Lispro	Injection	100 international units/mL	MAF	Type 1 & 2 diabetes mellitus
Insulin Lispro	Injection, prefilled pen	100 international units/mL	MAF	Type 1 & 2 diabetes mellitus
Insulin Lispro & Insulin Lispro Protamine	Injection, penfill	Insulin Lispro 25% + Insulin Lispro Protamine 75%	SDL
Insulin Lispro & Insulin Lispro Protamine	Injection, prefilled pen	Insulin Lispro 25% + Insulin Lispro Protamine 75%	MAF	Type 1 & 2 diabetes mellitus
Insulin Lispro & Insulin Lispro Protamine	Injection, prefilled pen	Insulin Lispro 50% + Insulin Lispro Protamine 50%	MAF	Type 1 & 2 diabetes mellitus
Insulin Soluble & Insulin Isophane (Human)	Injection	Insulin Soluble 30% + Insulin Isophane 70%	SDL
Insulin Soluble & Insulin Isophane (Human)	Injection, penfill	Insulin Soluble 30% + Insulin Isophane 70%	SDL
Insulin Soluble (Human)	Injection	100 international units/mL	SDL
Insulin Soluble (Human)	Injection, penfill	100 international units/mL	SDL
Interferon Alfa-2a	Injection	3 million international units/0.5 mL	SDL
Intraperitoneal Dialysis	Solution	Dextrose 1.5%, 2.5% or 4.25% with Ca2+ 1.25 mmol/L, Na+ 132 mmol/L, Mg2+ 0.25 mmol/L, Cl- 95 mmol/L, Lactate 40 mmol/L; Dextrose 1.5%, 2.5% or 4.25% with Ca2+ 2.57 mmol/L, Na+ 132 mmol/L, Mg2+ 0.25 mmol/L, Cl- 96 mmol/L, Lactate 40 mmol/L	SDL
Iodine	Topical solution	0.5%, 1.0%, 2.5%	SDL
Iodine Aqueous	Oral solution	Iodine 5% + Potassium iodide 10%	SDL
Ipratropium Bromide	Inhaler	20 mcg/dose	SDL
Ipratropium Bromide	Nebulisation solution	0.025%	SDL
Irinotecan Hydrochloride Trihydrate	Infusion	20 mg/mL	SDL
Iron (as Polymaltose)	Oral drops	50 mg/mL	SDL
Iron (as Polymaltose)	Tablet	100 mg	SDL
Iron (as Sucrose)	Injection	100 mg/5 mL	SDL
Isoniazid	Tablet	100 mg, 300 mg	SDL
Isoprenaline Hydrochloride	Injection	0.2 mg/mL, 1 mg/mL	SDL
Isoprenaline Sulfate	Injection	0.2 mg/mL, 1 mg/mL	SDL
Isosorbide Dinitrate	Tablet	10 mg	SDL
Isosorbide Mononitrate	Sustained-release tablet	60 mg	SDL
Itraconazole	Capsule	100 mg	SDL
Itraconazole	Oral solution	10 mg/mL	MAF	For prophylaxis of invasive fungal infections in high risk patients (such as anticipated to have prolonged neutropenia) and haematopoietic stem cell transplant recipients
Ivabradine	Tablet	5 mg, 7.5 mg	MAF	Treatment of chronic heart failure in patients with New York Heart Association (NYHA) class II to IV stable chronic heart failure with systolic dysfunction (LVEF of 35% or less), and who are in sinus rhythm with a heart rate of 75 bpm or more, and who are given concomitant standard medical management including the maximum tolerated dose of beta-blocker therapy, angiotensin converting enzyme inhibitors and aldosterone antagonists, unless contraindicated or not tolerated

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class
Kanamycin	Injection	1 g	SDL
Kaolin, Magnesium Carbonate (light) & Sodium Bicarbonate	Oral suspension	Kaolin 20% + Magnesium Carbonate (light) 5% + Sodium Bicarbonate 5%	SDL
Ketoprofen	Enteric-coated tablet	100 mg	SDL
Ketoprofen	Gel	2.5%	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
L-Arginine	Capsule	500 mg	MAF	1) Treatment of mitochondrial diseases including MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like episodes) 2) Treatment of urea cycle defects
L-Arginine	Injection	4.2 g/20 mL, 5 g/10 mL	MAF	1) Treatment of mitochondrial diseases including MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like episodes) 2) Treatment of urea cycle defects
L-Arginine	Tablet	500 mg	MAF	1) Treatment of mitochondrial diseases including MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like episodes) 2) Treatment of urea cycle defects
L-Asparaginase	Injection	10,000 international units	SDL
L-Citrulline	Capsule	750 mg	MAF	1) Treatment of hyperammonemia secondary to urea cycle disorders (proximal urea cycle defect, ornithine transcarbamylase deficiency or carbamoyl phosphate synthetase deficiency). 2) Acute treatment of mitochondrial diseases including MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like episodes)
L-Citrulline	Powder	5 g	MAF	1) Treatment of hyperammonemia secondary to urea cycle disorders (proximal urea cycle defect, ornithine transcarbamylase deficiency or carbamoyl phosphate synthetase deficiency). 2) Acute treatment of mitochondrial diseases including MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like episodes)
L-Isoleucine	Powder	100 mg/1.5 g	MAF	Treatment of Maple Syrup Urine Disease
L-Valine	Powder	100 mg/1.5 g	MAF	Treatment of Maple Syrup Urine Disease
Lactulose	Syrup	3.3 g/5 mL, 3.35 g/5 mL	SDL
Lamivudine	Tablet	100 mg, 150 mg	SDL
Lamotrigine	Dispersible tablet	5 mg	SDL
Lamotrigine	Tablet	50 mg, 100 mg	SDL
Land Snakes Antivenom	Concentrate for infusion	-	SDL
Latanoprost	Eye drops	0.005%	SDL
Leflunomide	Tablet	20 mg, 100 mg	MAF	1) Treatment of active psoriatic arthritis where other disease modifying drugs are ineffective and/ or inappropriate 2) Treatment of active rheumatoid arthritis where other disease modifying drugs are ineffective and/ or inappropriate
Letrozole	Tablet	2.5 mg	SDL
Leuprorelin Acetate	Injection	3.75 mg, 7.5 mg, 11.25 mg, 22.5 mg, 30 mg, 45 mg, 5 mg/mL	MAF	LHRH agonist is recommended: 1) As primary therapy for men with locally advanced or metastatic prostate cancer 2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy 3) For men with prostate cancer who have a biochemical relapse LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer
Levetiracetam	Concentrate for infusion	100 mg/mL	MAF	1) As a 2nd line agent for the management of epilepsy in adults and children 2) As adjunctive therapy or monotherapy in patients who have inadequate seizure control or intolerable adverse effects with 1st line agents, or where the use of 1st line agents is contraindicated
Levetiracetam	Oral solution	100 mg/mL	MAF	1) As a 2nd line agent for the management of epilepsy in adults and children 2) As adjunctive therapy or monotherapy in patients who have inadequate seizure control or intolerable adverse effects with 1st line agents, or where the use of 1st line agents is contraindicated
Levetiracetam	Tablet	250 mg, 500 mg, 1 g	MAF	1) As a 2nd line agent for the management of epilepsy in adults and children 2) As adjunctive therapy or monotherapy in patients who have inadequate seizure control or intolerable adverse effects with 1st line agents, or where the use of 1st line agents is contraindicated
Levocarnitine	Capsule	500 mg	MAF	Prevention of primary and secondary carnitine deficiency due to detoxification
Levocarnitine	Injection	1 g/5 mL	MAF	Prevention of primary and secondary carnitine deficiency due to detoxification
Levocarnitine	Oral solution	500 mg/10 mL	MAF	Prevention of primary and secondary carnitine deficiency due to detoxification
Levodopa & Benserazide	Capsule	Levodopa 100 mg + Benserazide 25 mg	SDL
Levodopa & Benserazide	Tablet	Levodopa 200 mg + Benserazide 50 mg	SDL
Levodopa & Benserazide	Controlled-release capsule	Levodopa 100 mg + Benserazide 25 mg	SDL
Levodopa & Carbidopa	Tablet	Levodopa 100 mg + Carbidopa 25 mg, Levodopa 250 mg + Carbidopa 25 mg	SDL
Levodopa & Carbidopa	Sustained-release tablet	Levodopa 200 mg + Carbidopa 50 mg	SDL
Levodopa, Carbidopa & Entacapone	Tablet	Levodopa 50 mg + Carbidopa 12.5 mg + Entacapone 200 mg, Levodopa 100 mg + Carbidopa 25 mg + Entacapone 200 mg, Levodopa 150 mg + Carbidopa 37.5 mg + Entacapone 200 mg, Levodopa 200 mg + Carbidopa 50 mg + Entacapone 200 mg	SDL
Levonorgestrel & Ethinylestradiol	Tablet	Levonorgestrel 0.15 mg + Ethinylestradiol 0.03 mg	SDL
Levothyroxine Sodium	Tablet	25 mcg, 50 mcg, 75 mcg, 100 mcg	SDL
Lidocaine	Ointment	5%	SDL
Lidocaine	Topical solution	4%	SDL
Lidocaine	Topical spray	10%	SDL
Lidocaine & Adrenaline	Injection	Lidocaine 2% + Adrenaline 1:80,000 (12.5 microgram/mL)	SDL
Lidocaine & Prilocaine	Cream	Lidocaine 2.5% + Prilocaine 2.5%	SDL
Lidocaine Hydrochloride	Gel	2%	SDL
Lidocaine Hydrochloride	Injection	1%	SDL
Lidocaine Hydrochloride	Oral solution (viscous)	2%	SDL
Lidocaine Hydrochloride	Injection (preservative-free)	1%, 2%	SDL
Linagliptin	Tablet	5 mg	MAF	For patients with type 2 diabetes mellitus and chronic kidney disease stages 3b, 4 or 5
Linezolid	Infusion	2 mg/mL	MAF	Treatment of patients with culture-positive vancomycin-resistant enterococci (VRE) bloodstream infections
Linezolid	Tablet	600 mg	MAF	Treatment of patients with culture-positive vancomycin-resistant enterococci (VRE) bloodstream infections
Liothyronine Sodium	Tablet	20 mcg	SDL
Liquid Paraffin	Oral emulsion	2.5 mL/5 mL	SDL
Liquid Paraffin	Liquid	-	SDL
Lisinopril	Tablet	5 mg, 10 mg, 20 mg	SDL
Lithium Carbonate	Controlled-release tablet	400 mg	SDL
Lomustine	Capsule	40 mg	SDL
Lopinavir & Ritonavir	Oral solution	Lopinavir 80 mg/mL + Ritonavir 20 mg/mL	SDL
Lopinavir & Ritonavir	Tablet	Lopinavir 200 mg + Ritonavir 50 mg	SDL
Loratadine	Syrup	5 mg/5 mL	SDL
Loratadine	Tablet	10 mg	SDL
Lorazepam	Tablet	0.5 mg, 1 mg	SDL
Losartan Potassium	Tablet	50 mg, 100 mg	SDL
Lovastatin	Tablet	20 mg	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Magnesium Carbonate & Sodium Bicarbonate	Oral suspension	Magnesium Carbonate 150 mg/5 mL + Sodium Bicarbonate 250 mg/5 mL + Aromatic Cardamom Tincture 0.15 mL/5 mL	SDL
Magnesium Chloride Hexahydrate, Potassium Chloride & Procaine Hydrochloride	Concentrate for infusion	Magnesium Chloride Hexahydrate 162.5 mg/mL (0.8 mmol/mL) + Potassium Chloride 59.5 mg/mL (0.8 mmol/mL) + Procaine Hydrochloride 13.64 mg/mL (0.05 mmol/mL)	SDL
Magnesium Sulfate	Crystal	-	SDL
Magnesium Sulfate	Injection	49.3%	SDL
Magnesium Sulfate	Injection	49.3% (2 mmol Mg2+/mL)	SDL
Magnesium Sulfate & Glycerin	Syrup	Magnesium Sulfate 35.4% + Glycerin 1.1%	SDL
Magnesium Trisilicate	Oral suspension	Magnesium Trisilicate 5% + Magnesium Carbonate 5% + Sodium Bicarbonate 5%	SDL
Malathion	Lotion	0.5%	SDL
Mannitol	Infusion	20%	SDL
Measles, Mumps, Rubella Vaccine	Injection	Measles Virus Vaccine (live-attenuated) minimum 1,000 CCID50/0.5 mL + Mumps Virus Vaccine (live-attenuated) minimum 12,500 CCID50/0.5 mL + Rubella Virus Vaccine (live-attenuated) minimum 1,000 CCID50/0.5 mL	SDL
Mebeverine Hydrochloride	Tablet	135 mg	SDL
Medroxyprogesterone Acetate	Injection	50 mg/mL	SDL
Medroxyprogesterone Acetate	Tablet	5 mg, 10 mg	SDL
Mefenamic Acid	Capsule	250 mg	SDL
Mefloquine	Tablet	250 mg	SDL
Melphalan	Injection	50 mg	SDL
Melphalan	Tablet	2 mg	SDL
Mercaptopurine	Tablet	50 mg	SDL
Meropenem	Injection	500 mg, 1 g	SDL
Mesalazine	Enema	2 g/30 mL	SDL
Mesalazine	Enteric-coated tablet	250 mg, 400 mg, 500 mg, 800 mg	SDL
Mesalazine	Slow-release tablet	500 mg	SDL
Mesalazine	Suppository	250 mg, 500 mg, 1 g	SDL
Mesna	Injection	100 mg/mL	SDL
Mesna	Tablet	400 mg, 600 mg	SDL
Metformin Hydrochloride	Tablet	250 mg, 500 mg, 850 mg	SDL
Methadone	Tablet	5 mg	SDL
Methionine	Oral powder	-	SDL
Methotrexate	Injection	50 mg/2 mL, 1 g/10 mL	SDL
Methotrexate	Injection (preservative-free)	50 mg/2 mL	SDL
Methotrexate	Tablet	2.5 mg	SDL
Methoxsalen	Lotion	0.01%, 0.05%, 0.1%, 0.75%	SDL
Methoxsalen	Capsule	10 mg	SDL
Methoxsalen	Tablet	10 mg	SDL
Methyl Salicylate	Cream	10%-20%	SDL
Methyl Salicylate	Solution	25%	SDL
Methylated Spirit	Topical solution	70%	SDL
Methyldopa	Tablet	125 mg, 250 mg	SDL
Methylphenidate Hydrochloride	Extended-release tablet	18 mg, 27 mg, 36 mg, 54 mg	MAF	Attention deficit hyperactivity disorder in children and adolescents aged < 18 years old
Methylphenidate Hydrochloride	Long-acting capsule	20 mg	MAF	Attention deficit hyperactivity disorder in children and adolescents aged < 18 years old
Methylphenidate Hydrochloride (Medikinet)	Modified-release capsule	5 mg, 10 mg, 20 mg, 30 mg, 40 mg	SDL
Methylphenidate Hydrochloride	Sustained-release tablet	20 mg	MAF	Attention deficit hyperactivity disorder in children and adolescents aged < 18 years old
Methylphenidate Hydrochloride	Tablet	10 mg	SDL
Methylprednisolone (as Sodium Succinate)	Injection	62.5 mg/mL	SDL
Metoclopramide Hydrochloride	Injection	5mg/mL	SDL
Metoclopramide Hydrochloride	Tablet	10 mg	SDL
Metronidazole	Infusion	5 mg/mL	SDL
Metronidazole	Tablet	200 mg	SDL
Miconazole	Oral gel	2%	SDL
Miconazole Nitrate	Cream	2%	SDL
Midazolam	Injection	5 mg/mL, 5 mg/5 mL	SDL
Midodrine Hydrochloride	Tablet	5 mg	SDL
Mirtazapine	Oral disintegrating tablet	15 mg, 30 mg	SDL
Mirtazapine	Tablet	30 mg	SDL
Mitomycin	Injection	2 mg, 10 mg	SDL
Mitoxantrone	Injection	2 mg/mL	SDL
Moclobemide	Tablet	150 mg	SDL
Mometasone Furoate	Nasal spray	0.05%	SDL
Morphine Sulfate	Controlled-release tablet	10 mg, 30 mg	SDL
Morphine Sulfate	Injection	10 mg/mL	SDL
Morphine Sulfate	Oral solution	10 mg/5 mL	SDL
Morphine Sulfate	Syrup	1 mg/mL	SDL
Multivitamin for Paediatrics	Oral solution	A combination preparation of vitamins, minerals and/or nutrients, which includes at least 3 of the following: Ascorbic acid, Riboflavine, Nicotinamide, Thiamine, Pyridoxine, Calciferol, Cyanocobalamin, Vitamin A	SDL
Mycophenolate Mofetil	Capsule	250 mg	SDL
Mycophenolate Mofetil	Infusion	500 mg	SDL
Mycophenolate Mofetil	Tablet	500 mg	SDL
Mycophenolate Sodium (Myfortic)	Enteric-coated Tablet	180 mg, 360 mg	MAF	Prevention of organ rejection in patients who have received a kidney transplant and are unable to tolerate mycophenolate mofetil due to gastrointestinal adverse effects

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Naloxone Hydrochloride	Injection	0.4 mg/mL	SDL
Nandrolone Decanoate	Injection	25 mg/mL	SDL
Naphazoline Hydrochloride & Pheniramine Maleate	Eye drops	Naphazoline Hydrochloride 0.025% + Pheniramine Maleate 0.3%	SDL
Neomycin Sulfate	Tablet	500 mg	SDL
Neomycin, Polymyxin B & Dexamethasone	Ear drops	Neomycin Sulfate 6,500 international units/mL + Polymyxin B Sulfate 10,000 international units/mL + Dexamethasone Sodium Metasulfobenzoate 1 mg/mL	SDL
Neostigmine Metilsulfate	Injection	2.5 mg/mL	SDL
Netupitant & Palonosetron	Capsule	Netupitant 300 mg & Palonosetron 0.5 mg	MAF	Prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
Nevirapine	Extended-release tablet	400 mg	SDL
Nevirapine	Tablet	200 mg	SDL
Nicotinic Acid	Tablet	50 mg	SDL
Nifedipine	Extended-release tablet	30 mg, 60 mg	SDL
Nifedipine	Tablet	10 mg	SDL
Nifedipine	Capsule	5 mg, 10 mg	SDL
Nitrazepam	Tablet	5 mg	SDL
Nitrofurantoin	Tablet	50 mg	SDL
Norepinephrine	Concentrate for infusion	4 mg/4 mL	SDL
Norethisterone	Tablet	5 mg	SDL
Nortriptyline	Capsule	10 mg, 25 mg	SDL
Nystatin	Oral suspension	100,000 units/mL	SDL
Nystatin	Vaginal tablet	100,000 units	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Olanzapine	Oral disintegrating tablet	5 mg, 10 mg	SDL
Olanzapine	Tablet	5 mg, 10 mg	SDL
Olive Oil	Ear drops	-	SDL
Omalizumab	Injection	150 mg	MAF	Checklist to be completed. As an add-on therapy to H₁-antihistamines for treating severe chronic spontaneous urticaria (CSU) in patients aged 12 years and older, with a mean weekly Urticaria Activity Score (UAS7) of 28 and above, despite the use of, or who are intolerant to, four-times registered dose of second generation non-sedating H₁-antihistamines. A maximum of six 300 mg doses of omalizumab should be administered for each treatment course. Re-treatment with omalizumab can be considered upon relapse for patients who achieve an adequate response during the previous treatment course. Adequate response to omalizumab is defined as a UAS7 score of six or below while on treatment.
Omeprazole	Capsule	20 mg	SDL
Omeprazole	Injection	40mg	SDL
Ondansetron	Injection	2 mg/mL	SDL
Ondansetron	Tablet	8 mg	SDL
Oral Rehydration Salts	Effervescent tablet	-	SDL
Oral Rehydration Salts	Oral powder for reconstitution	-	SDL
Oxaliplatin	Concentrate for infusion	50 mg/10 mL, 100 mg/50 mL	SDL
Oxaliplatin	Infusion	50 mg, 100 mg	SDL
Oxybutynin Chloride	Tablet	5 mg	SDL
Oxymetazoline Hydrochloride	Nasal drops	0.01%, 0.025%, 0.05%	SDL
Oxymetazoline Hydrochloride	Nasal spray	0.025%, 0.05%	SDL
Oxytocin	Injection	10 international units/mL	SDL
Oxytocin & Ergometrine Maleate	Injection	Oxytocin 5 international units/mL + Ergometrine Maleate 0.5 mg/mL	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Paclitaxel	Concentrate for infusion	6 mg/mL	SDL
Pamidronate Disodium	Infusion	30 mg, 90 mg	MAF	1) Treatment of metastatic bone lesions from breast cancer and advanced multiple myeloma 2) Treatment of hypercalcaemia of malignancy
Pancuronium Bromide	Concentrate for infusion	2 mg/mL	SDL
Pantopazole	Injection	40 mg	SDL
Paracetamol	Infusion	500 mg/50 mL, 1,000 mg/100 mL	SDL
Paracetamol	Oral suspension	120 mg/5 mL	SDL
Paracetamol	Rectal suppository	125 mg, 250 mg, 325 mg, 650 mg	SDL
Paracetamol	Tablet	120 mg, 500 mg	SDL
Paracetamol & Orphenadrine Citrate	Tablet	Paracetamol 450 mg + Orphenadrine Citrate 35 mg	SDL
Paraffin	Liquid	-	SDL
Paraffin Soft & Paraffin Liquid	Emulsion	Soft Paraffin 50% + Liquid Paraffin 50%	SDL
Peginterferon Alfa-2a	Injection	135 mcg/0.5 mL, 180 mcg/0.5 mL	MAF	1) Treatment, in combination with ribavirin, of chronic hepatitis C infection in naive adult patients and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin 2) Treatment for a duration of up to 48 weeks, in adult patients with HBeAg-positive and HBeAg-negative chronic hepatitis B infection with compensated liver disease and evidence of viral replication and liver inflammation.
Penicillamine	Capsule	250 mg	SDL
Pethidine Hydrochloride	Injection	50 mg/mL	SDL
Phenazopyridine Hydrochloride	Tablet	100 mg	SDL
Phenobarbital Sodium	Injection	200 mg/mL	SDL
Phenobarbitone	Tablet	10 mg, 30 mg, 60 mg	SDL
Phenol (in almond oil)	Injection	5%	SDL
Phenoxymethylpenicillin	Tablet	250 mg	SDL
Phenylephrine Hydrochloride	Single-use eye drops	2.5%, 10%	SDL
Phenylephrine Hydrochloride	Eye drops	2.5%, 10%	SDL
Phenytoin	Oral suspension	125 mg/5 mL	SDL
Phenytoin Sodium	Injection	50 mg/mL	SDL
Phenytoin Sodium	Capsule	30 mg, 100 mg	SDL
Physostigmine Salicylate	Injection	1 mg/mL	SDL
Phytomenadione	Injection	10 mg/mL	SDL
Pilocarpine Hydrochloride	Eye drops	2%, 4%	SDL
Pilocarpine Nitrate	Single-use eye drops	2%	SDL
Piperacillin & Tazobactam	Injection	Piperacillin 4 g + Tazobactam 0.5 g	SDL
Piroxicam	Capsule	10 mg, 20 mg	SDL
Plasma-derived Factor VIII	Injection	250 international units, 500 international units, 1000 international units	SDL
Plasma-derived Factor VIII & Von Willebrand Factor	Injection	Plasma-derived Factor VIII 250 international units, 500 international units, 1000 international units + Von Willebrand Factor range 100 international units to 3200 international units	SDL
Podophyllum Resin	Paint	0.25%, 0.5%	SDL
Poliomyelitis Vaccine (live-attenuated)	Oral suspension	Poliovirus Vaccine (type 1 live-attenuated) minimum 1,000,000 TCID50/0.5 mL + Poliovirus Vaccine (type 2 live-attenuated) minimum 100,000 TCID50/0.5 mL + Poliovirus Vaccine (type 3 live-attenuated) minimum 300,000 TCID50/0.5 mL	SDL
Poractant alfa	Intratracheal suspension	120 mg/1.5 mL	SDL
Posaconazole	Delayed-release tablet	100 mg	MAF	For prophylaxis of invasive fungal infections in high risk patients (such as anticipated to have prolonged neutropenia) and haematopoietic stem cell transplant recipients
Posaconazole	Oral suspension	40 mg/mL	MAF	For prophylaxis of invasive fungal infections in high risk patients (such as anticipated to have prolonged neutropenia) and haematopoietic stem cell transplant recipients
Potassium Chloride	Slow-release tablet	600 mg	SDL
Potassium Chloride	Oral solution	500 mg/5 mL	SDL
Potassium Chloride	Concentrate for infusion	7.45%	SDL
Potassium Chloride	Infusion	0.1 mmol/mL, 0.2 mmol/mL, 0.4 mmol/mL	SDL
Potassium Chloride & Sodium Chloride	Infusion	Potassium Chloride 0.15% + Sodium Chloride 0.9%	SDL
Potassium Citrate	Oral solution	500 mg/5 mL	SDL
Potassium Permanganate	Crystals	100%	SDL
Potassium Permanganate	Topical solution	0.1%	SDL
Potassium Phosphate Monobasic	Concentrate for infusion	1 mmol/mL (0.1361 g/mL)	SDL
Povidone-Iodine	Topical solution	10%	SDL
Pralidoxime Chloride	Injection	500 mg/20 mL	SDL
Pramipexole Dihydrochloride Monohydrate	Tablet	0.125 mg, 1 mg	SDL
Pravastatin Sodium	Tablet	20 mg	SDL
Prazosin	Tablet	1 mg, 5 mg	SDL
Prednisolone	Syrup	10 mg/5 mL	SDL
Prednisolone	Tablet	1 mg, 5 mg, 20 mg	SDL
Primaquine	Tablet	7.5 mg, 15 mg	SDL
Probenecid	Tablet	500 mg	SDL
Procainamide Hydrochloride	Injection	100 mg/mL	SDL
Procaine Hydrochloride	Lotion (in spirit 70%)	2%	SDL
Procarbazine	Capsule	50 mg	SDL
Prochlorperazine Maleate	Tablet	5 mg	SDL
Prochlorperazine Mesilate	Injection	12.5 mg/mL	SDL
Progesterone	Injection	50 mg/mL	SDL
Promethazine Hydrochloride	Syrup	5 mg/5mL	SDL
Promethazine Hydrochloride	Injection	25 mg/mL	SDL
Promethazine Hydrochloride	Syrup	5 mg/5 mL	SDL
Promethazine Theoclate	Tablet	25 mg	SDL
Propantheline Bromide	Tablet	15 mg	SDL
Proparacaine Hydrochloride	Eye drops	0.5%	SDL
Propofol	Injection	10 mg/mL	SDL
Propranolol Hydrochloride	Injection	1 mg/mL	SDL
Propranolol Hydrochloride	Tablet	10 mg, 40 mg, 80 mg	SDL
Propylene Glycol	Solution	40%	SDL
Propylthiouracil	Tablet	50 mg	SDL
Protamine Sulfate	Injection	1% (10 mg/mL)	SDL
Pyrazinamide	Tablet	500 mg	SDL
Pyridostigmine Bromide	Tablet	10 mg, 60 mg	SDL
Pyridoxine Hydrochloride	Tablet	10 mg, 50 mg	SDL
Pyrimethamine	Tablet	25 mg	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Quetiapine	Tablet	25 mg, 100 mg, 200 mg	SDL
Quinine Sulfate	Tablet	300 mg	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Rabies Virus Vaccine (Inactivated)	Injection	Minimum 2.5 international units	SDL
Ranitidine	Injection	50 mg/2 mL	SDL
Raltegravir	Tablet	400 mg, 600 mg	MAF	In combination with other antiretroviral agents for the treatment of HIV-1 infection
Recombinant Factor VIII (Xyntha)	Injection	250 international units, 500 international units, 1000 international units, 2000 international units	SDL
Ribavirin	Capsule	200 mg	MAF	Treatment of chronic hepatitis C infection (all genotypes)
Ribavirin	Tablet	200 mg	MAF	Treatment of chronic hepatitis C infection (all genotypes)
Rifampicin	Capsule	150 mg, 300 mg	SDL
Rifampicin	Suspension	100 mg/5 mL	SDL
Rifaximin	Tablet	550 mg	SDL
Rilpivirine	Tablet	25 mg	SDL
Risedronate Sodium	Tablet	5 mg, 35 mg	MAF	1) For patients with osteoporosis (T-score ≤ -2.5) 2) For patients with osteopenia (T-score ≤ -1.5) and a history of non-trauma induced fracture
Risperidone	Oral solution	1 mg/mL	SDL
Risperidone	Tablet	0.5 mg, 1 mg, 2 mg	SDL
Ritonavir	Tablet	100 mg	SDL
Rituximab	Concentrate for infusion	100 mg/10 mL, 500 mg/50 mL	MAF	1) Treatment of patients with CD20 positive diffuse large B cell lymphoma 2) Treatment of patients with CD20 positive follicular non-Hodgkin's lymphoma
Rivaroxaban	Tablet	15 mg, 20 mg	MAF	1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)* and CHA2DS2-VASc score of 1 or more for men, and 2 or more for women *This excludes patients with rheumatic mitral stenosis or prosthetic heart valves 2) Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE in adults. MAF assistance does not apply to patients with isolated distal DVT
Rivastigmine	Transdermal patch	4.6 mg/24 hr, 9.5 mg/24 hr, 13.3 mg/24 hr	MAF	Checklist to be completed 1) Rivastigmine patch formulation (4.6 mg/24 hr and 9.5 mg/24 hr) for the treatment of moderately severe dementia associated with Parkinson's disease in patients who have behavioural symptoms 2) Rivastigmine patch formulation (4.6 mg/24 hr, 9.5 mg/24 hr and 13.3 mg/24 hr) for the treatment of moderately severe dementia associated with Alzheimer's disease in patients who have behavioural symptoms
Ropinirole	Tablet	0.25 mg, 1 mg, 2 mg	SDL
Rubella Virus Vaccine (live-attenuated)	Injection	Minimum 1,000 TCID 50/0.5 mL	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Salbutamol	Inhaler	100 mcg/dose	SDL
Salbutamol	Nebulisation solution	0.5%	SDL
Salbutamol	Concentrate for infusion	5 mg/5 mL	SDL
Salbutamol	Oral liquid	2 mg/5 mL	SDL
Salbutamol	Tablet	2 mg	SDL
Salicylic Acid	Cream	2%, 20%	SDL
Salicylic Acid	Ointment	1%, 2%, 5%, 10%, 20%, 40%	SDL
Salicylic Acid & Lactic Acid	Topical solution	Salicylic Acid 16.7% + Lactic Acid 16.7% Collodion	SDL
Salmeterol & Fluticasone Propionate	Inhaler	Salmeterol 25 mcg/dose + Fluticasone Propionate 50 mcg/dose, Salmeterol 25 mcg/dose + Fluticasone Propionate 125 mcg/dose, Salmeterol 25 mcg/dose + Fluticasone Propionate 250 mcg/dose	SDL
Salmeterol & Fluticasone Propionate	Powder inhaler	Salmeterol 50 mcg/dose + Fluticasone Propionate 100 mcg/dose, Salmeterol 50 mcg/dose + Fluticasone Propionate 250 mcg/dose, Salmeterol 50 mcg/dose + Fluticasone Propionate 500 mcg/dose	SDL
Sea Snake Venom Antiserum	Concentrate for infusion	1,000 units/dose	SDL
Selenium Sulfide	Topical suspension	2.5%	SDL
Sennosides	Tablet	7.5 mg	SDL
Sertraline	Tablet	50 mg	SDL
Sevelamer Carbonate	Tablet	800 mg	MAF	Treatment of hyperphosphataemia in patients with chronic kidney disease who have persistent hyperphosphataemia despite optimising treatment with calcium-based phosphate binders, or who are unable to tolerate calcium-based phosphate binders due to hypercalcaemia.
Silicone Cream	Cream	Dimethicone 10%, Chlorocresol 0.1%	SDL
Simeticone	Oral suspension	100 mg/mL	SDL
Simvastatin	Tablet	10 mg, 20 mg	SDL
Sirolimus	Tablet	0.5 mg, 1 mg, 2 mg	MAF	For kidney transplant immunosuppression in patients with: 1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR 2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR 3) History of CNI drug hypersensitivity
Sirolimus	Oral solution	1 mg/mL	MAF	For kidney transplant immunosuppression in patients with: 1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR 2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR 3) History of CNI drug hypersensitivity
Sodium Alginate, Sodium Bicarbonate & Calcium Carbonate	Oral suspension	Sodium Alginate 500 mg/10 mL + Sodium Bicarbonate 267 mg/10 mL + Calcium Carbonate 160 mg/10 mL	SDL
Sodium Benzoate	Injection	2 g/10 mL	SDL
Sodium Benzoate	Powder	5 g, 1 kg	SDL
Sodium Benzoate	Tablet	500 mg	SDL
Sodium Bicarbonate	Infusion	4.2%, 8.4%	SDL
Sodium Bicarbonate	Injection	4.2%, 8.4%	SDL
Sodium Bicarbonate	Capsule	500 mg	SDL
Sodium Bicarbonate	Powder	Minimum 99%	SDL
Sodium Bicarbonate & Sodium Chloride	Powder	9 parts Sodium Bicarbonate + 1 part Sodium Chloride	SDL
Sodium Calcium Edetate	Injection	500 mg/10 mL	SDL
Sodium Chloride	Infusion	0.45%, 0.9%, 3%, 20%	SDL
Sodium Chloride	Irrigation solution	0.9%	SDL
Sodium Chloride	Injection	0.45%, 0.9%, 3%, 20%	SDL
Sodium Chloride	Eye drops	0.9%, 5%	SDL
Sodium Chloride	Eye ointment	5%	SDL
Sodium Chloride & Dextrose	Sustained-release tablet	Sodium Chloride 500 mg + Dextrose 200 mg	SDL
Sodium Chloride, Calcium Chloride Dihydrate & Potassium Chloride	Infusion	Sodium Chloride 8.6 g/L + Calcium Chloride Dihydrate 0.33 g/L + Potassium Chloride 0.3 g/L	SDL
Sodium Nitrite	Injection	3%	SDL
Sodium Nitroprusside	Injection	50 mg/2 ml	SDL
Sodium Polystyrene Sulfonate	Oral suspension	15 g/60 mL	SDL
Sodium Polystyrene Sulfonate	Powder for oral suspension	99%	SDL
Sodium Tetradecyl Sulfate	Injection	1%, 3%	SDL
Sodium Thiosulfate	Injection	25%	SDL
Sodium Valproate	Controlled-release tablet	200 mg, 300 mg, 500 mg	SDL
Sodium Valproate	Enteric-coated tablet	200 mg	SDL
Sodium Valproate	Injection	400 mg	SDL
Sodium Valproate	Syrup	200 mg/5 mL	SDL
Sofosbuvir & Velpatasvir	Tablet	Sofosbuvir 400 mg + Velpatasvir 100 mg	MAF	Treatment of chronic hepatitis C infection (all genotypes) in treatment-naïve, or pegylated interferon plus ribavirin (PR)-experienced or NS3/4A protease inhibitor (boceprevir, simeprevir, telaprevir)-experienced adults. Sofosbuvir/velpatasvir should be used in line with the recommended treatment regimen and duration: • 12 weeks’ treatment of sofosbuvir/velpatasvir for patients with hepatitis C virus (all genotypes) without cirrhosis or with compensated cirrhosis (Child-Pugh A). For patients with genotype 3, the addition of ribavirin may be considered in patients who are treatment-experienced or have compensated cirrhosis (Child-Pugh A). • 12 weeks’ treatment of sofosbuvir/velpatasvir in combination with ribavirin for patients with hepatitis C virus (all genotypes) with decompensated cirrhosis (Child-Pugh B or C).
Solifenacin Succinate	Tablet	5 mg	SDL
Somatostatin (as Acetate)	Infusion	3 mg	SDL
Somatropin	Prefilled pen	5 mg/1.5 mL, 10 mg/1.5 mL	MAF	Treatment of children with short stature due to conditions associated with growth failure *Somatropin is not recommended for the treatment of idiopathic short stature
Somatropin	Injection	3.33 mg, 4 mg, 6 mg	MAF	Treatment of children with short stature due to conditions associated with growth failure *Somatropin is not recommended for the treatment of idiopathic short stature
Spironolactone	Tablet	25 mg	SDL
Stiripentol	Capsule	250 mg, 500 mg	MAF	Treatment of status epilepticus in Dravet syndrome
Stiripentol	Oral suspension	250 mg, 500 mg	MAF	Treatment of status epilepticus in Dravet syndrome
Streptokinase	Infusion	1.5 million international units	SDL
Streptomycin	Injection	1 g	SDL
Sulfadiazine Silver	Cream	1%	SDL
Sulfamethoxazole & Trimethoprim	Concentrate for infusion	Sulfamethoxazole 80 mg/mL + Trimethoprim 16 mg/mL	SDL
Sulfamethoxazole & Trimethoprim	Suspension	Trimethoprim 40 mg/5 mL + Sulphamethoxazole 200 mg/5 mL	SDL
Sulfamethoxazole & Trimethoprim	Tablet	Trimethoprim 20 mg + Sulphamethoxazole 100 mg, Trimethoprim 80 mg + Sulphamethoxazole 400 mg	SDL
Sulfasalazine	Enteric-coated tablet	500 mg	SDL
Sulphur & Salicylic Acid	Cream	Sulphur 4% + Salicylic Acid 2%	SDL
Sulphur, Resorcinol & Calamine	Lotion	Sulphur 4% + Resorcinol 2% + Calamine 10%	SDL
Sulphur, Zinc Oxide, Resorcinol & Calamine	Cream	Sulphur 4% + Zinc Oxide 8% + Resorcinol 2% + Calamine 8%	SDL
Sulpiride	Tablet	200 mg	SDL
Sumatriptan	Tablet	50 mg	SDL
Suxamethonium Chloride	Injection	50 mg/mL	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Tacrolimus	Prolonged-release capsule	0.5 mg, 1 mg, 5 mg	SDL
Tacrolimus	Capsule	0.5 mg, 1 mg, 5 mg	SDL
Tacrolimus	Concentrate for infusion	5 mg/mL	SDL
Tacrolimus	Ointment	0.1%	MAF	Treatment of moderate to severe atopic dermatitis in adults and adolescents (16 years of age and above) who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids
Tacrolimus	Ointment	0.03%	MAF	1) Treatment of moderate to severe atopic dermatitis in adults and adolescents (16 years of age and above) who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids 2) Treatment of moderate to severe atopic dermatitis in children (2 years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids
Tamoxifen	Tablet	10 mg, 20 mg	SDL
Telmisartan	Tablet	40 mg, 80 mg	SDL
Temozolomide	Capsule	20 mg, 100 mg	SDL
Tenofovir Disoproxil Fumarate	Tablet	300 mg	SDL
Terazosin	Tablet	2 mg, 5 mg	SDL
Testosterone Cipionate	Injection	100 mg/mL	SDL
Tetanus Immunoglobulin (Human)	Injection	250 units/dose	SDL
Tetanus Toxoid Vaccine	Injection	Minimum 40 international units/0.5 mL	SDL
Tetracycline Hydrochloride	Ointment	3%	SDL
Tetracycline Hydrochloride	Capsule	250 mg	SDL
Thalidomide	Capsule	50 mg	SDL
Theophylline	Sustained-release tablet	125 mg, 200 mg, 250 mg, 300 mg	SDL
Theophylline	Syrup	80 mg/15 mL	SDL
Thiamine Hydrochloride	Injection	100 mg/2 mL, 100 mg/mL	SDL
Thiamine Hydrochloride	Tablet	10 mg	SDL
Thiopental Sodium	Injection	0.5 g, 1 g	SDL
Thrombin	Topical solution	5,000 international units/5 mL	SDL
Ticagrelor	Tablet	90 mg	MAF	Prevention of thrombotic events (cardiovascular death, myocardial infarction and stroke) in adults with acute coronary syndromes, that is, people: • with ST-segment-elevation myocardial infarction (STEMI); or • with non-ST-segment-elevation myocardial infarction (NSTEMI); or • with unstable angina requiring hospitalisation - defined as ST or T wave changes on electrocardiogram suggestive of ischaemia plus one of the following characteristics: - age 60 years and older; - previous myocardial infarction; - previous coronary artery bypass grafting (CABG); - coronary artery disease with stenosis of 50% or more in at least two vessels; - previous ischaemic stroke; - previous transient ischaemic attack; - carotid stenosis of at least 50%; - cerebral revascularisation; - diabetes mellitus; - peripheral arterial disease; or - chronic renal dysfunction, defined as a creatinine clearance of less than 60 ml per minute per 1.73m² of body surface area. Ticagrelor should be used in combination with low-dose aspirin for up to 12 months.
Ticlopidine Hydrochloride	Tablet	250 mg	SDL
Timolol Maleate	Eye drops	0.25%, 0.5%	SDL
Tioguanine	Tablet	40 mg	SDL
Tolbutamide	Tablet	500 mg	SDL
Tolterodine Tartrate	Extended-release capsule	4 mg	SDL
Tolterodine Tartrate	Tablet	1 mg, 2 mg	SDL
Topiramate	Tablet	25 mg, 50 mg, 100 mg	SDL
Tramadol Hydrochloride	Capsule	50 mg	SDL
Tramadol Hydrochloride	Tablet	50 mg	SDL
Tranexamic Acid	Injection	100 mg/mL	SDL
Tranexamic Acid	Tablet	500 mg	SDL
Trastuzumab (Herceptin)	Infusion	440 mg	MAF	1) Treatment of women with HER2-positive early breast cancer who are axillary lymph node positive 2) Treatment of women with HER2-positive early breast cancer with tumour size greater than 1 cm and are axillary lymph node negative Checklist to be completed 3) Treatment of HER2-positive metastatic breast cancer, in the following circumstances: In combination with a taxane for patients who have not received chemotherapy for their metastatic disease, or In combination with an aromatase inhibitor for postmenopausal patients with hormone-receptor positive metastatic breast cancer, not previously treated with trastuzumab
Trastuzumab Biosimilar (Ogivri)	Injection	440 mg	SDL
Tretinoin	Capsule	10 mg	SDL
Triamcinolone Acetonide	Injection	10 mg/mL	SDL
Triamcinolone Acetonide	Nasal spray	55 mcg/dose	SDL
Triamterene & Hydrochlorothiazide	Tablet	Triamterene 50 mg + Hydrochlorothiazide 25 mg	SDL
Trifluoperazine	Tablet	1 mg, 5 mg	SDL
Trimethoprim	Oral suspension	50 mg/5 mL	SDL
Trimethoprim	Tablet	100 mg	SDL
Tropicamide	Eye drops	0.5%, 1%	SDL
Tropicamide	Single-use eye drops	1%	SDL
Typhoid Vaccine (salmonella typhi Vi polysaccharide Ty2 strain) (Killed vaccine)	Injection	25 mcg/0.5 mL	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class
Umeclidinium	Powder inhaler	62.5 mcg/dose	SDL
Umeclidinium & Vilanterol	Powder inhaler	Umeclidinium 62.5 mcg/dose + Vilanterol 25 mcg/dose	SDL
Urea	Cream	5%, 10%	SDL
Ursodeoxycholic Acid	Capsule	250 mg	SDL
Ursodeoxycholic Acid	Suspension	50 mg/mL	SDL
Ursodeoxycholic Acid	Tablet	500 mg	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Valganciclovir	Tablet	450 mg	SDL	Prevention of cytomegalovirus infection after solid organ transplant
Valsartan	Tablet	80 mg, 160 mg	SDL
Vancomycin	Infusion	500 mg	SDL
Vasopressin	Injection	20 pressor units/mL	SDL
Venlafaxine	Extended-release capsule	75 mg, 150 mg	SDL
Verapamil Hydrochloride	Injection	2.5 mg/mL	SDL
Verapamil Hydrochloride	Tablet	40 mg	SDL
Vinblastine Sulfate	Injection	10 mg	SDL
Vincristine Sulfate	Injection	1 mg	SDL
Vitamin A	Capsule	10,000 units	SDL
Vitamin B Complex	Injection	Thiamine Hydrochloride 10 mg/2 mL + Sodium Riboflavin Phosphate 4 mg/2 mL + Nicotinic Acid 40 mg/2 mL + Panthenol 6 mg/2 mL + Biotin 5 mg/2 mL + Pyridoxine Hydrochloride 4 mg/2 mL + Cyanocobalamin 8 mcg/2 mL	SDL
Vitamin B Complex	Tablet	Thiamine 3 mg + Riboflavine 1.5 mg + Nicotinamide 10 mg + Pyridoxine 0.5 mg	SDL
Voriconazole	Infusion	200 mg	MAF	1) Treatment of invasive aspergillosis 2) Treatment of candidaemia in non-neutropenic patients 3) Treatment of fluconazole-resistant candidiasis 4) Treatment of serious infections from Scedosporium and Fusarium species
Voriconazole	Oral suspension	40 mg/mL	MAF	1) Treatment of invasive aspergillosis 2) Treatment of candidaemia in non-neutropenic patients 3) Treatment of fluconazole-resistant candidiasis 4) Treatment of serious infections from Scedosporium and Fusarium species
Voriconazole	Tablet	50 mg, 200 mg	MAF	1) Treatment of invasive aspergillosis 2) Treatment of candidaemia in non-neutropenic patients 3) Treatment of fluconazole-resistant candidiasis 4) Treatment of serious infections from Scedosporium and Fusarium species

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Warfarin Sodium	Tablet	1 mg, 3 mg, 5 mg	SDL
White Soft Paraffin	Ointment	-	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Yellow Fever Virus Vaccine (live-attenuated)	Injection	Minimum 1,000 LD50 units	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Zidovudine	Capsule	100 mg	SDL
Zoledronic Acid	Infusion	5 mg/100 mL	MAF	1) For patients with osteoporosis (T score ≤ -2.5) and who are unable to tolerate or follow the administration instructions for oral bisphosphonates 2) For patients with FRAX of ≥ 20 for major osteoporotic fractures and ≥ 3 for hip fractures and who are unable to tolerate or follow the administration instructions for oral bisphosphonates
Zoledronic Acid	Infusion	4 mg	MAF	1) Treatment of metastatic bone lesions from solid tumours and multiple myeloma 2) Treatment of hypercalcaemia of malignancy
Zuclopenthixol Acetate	Injection	50 mg/mL	SDL
Zuclopenthixol Decanoate	Injection	200 mg/mL	SDL

Drug Subsidies & Schemes

Who is Eligible?

What drugs can I claim for?

List of Drugs* (as of 1 October 2020)

Frequently Asked Questions

What if my drug isn't listed?

How do I apply?